The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $297.64

Today's change+1.12 +0.38%
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $297.64

Today's change+1.12 +0.38%
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Ishares Nasdaq Biotechnology Hits New 20-day High

Ishares Nasdaq Biotechnology closed up Friday by (U.S.)$1.12 or 0.38% to (U.S.)$297.64 and setting a new 20-day high. Over the last five days, shares have gained 3.53% and are currently 2.01% off of the 52-week high. Shares have underperformed the S&P 500 by 6.73% during the last year.

Key company metrics

  • Open(U.S.) $296.42
  • Previous close(U.S.) $296.52
  • High(U.S.) $298.31
  • Low(U.S.) $295.67
  • Bid / Ask(U.S.) $296.50 / (U.S.) $298.60
  • YTD % change+12.16%
  • Volume569,883
  • Average volume (10-day)818,537
  • Average volume (1-month)924,330
  • Average volume (3-month)1,204,885
  • 52-week range(U.S.) $240.30 to (U.S.) $303.74
  • Beta1.36
  • Trailing P/E3.28×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.49
  • Dividend yield0.17%
  • Trailing EPS(U.S.) $90.83
Updated April 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.51%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

View more News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Sep 30, 201409/30/2014Mar 31, 201403/31/2014Sep 30, 201309/30/2013
Revenue92198
Total other revenue--------
Total revenue92198
Gross profit--------
Total cost of revenue--------
Total operating expense1612118
Selling / general / administrative1612118
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-79-20
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,572718446878
Income after tax1,572718446878
Income tax, total0000
Net income1,572718446878
Total adjustments to net income--------
Net income before extra. items1,572718446878
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,572718446878
Inc. avail. to common incl. extra. items1,572718446878
Diluted net income1,572718446878
Dilution adjustment----0--
Diluted weighted average shares29202319
Diluted EPS excluding extraordinary itemsvalue per share54.7736.0619.0345.62
Dividends per sharevalue per share0.000.450.000.07
Diluted normalized EPSvalue per share54.7736.0619.0345.62